<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="vaccines are developed, with an example being the licensed recombinant" exact="hepatitis" post="B vaccine (45). The key therefore to an effective"/>
 <result pre="intensively used to develop vaccines against various pathogens (54, 55)," exact="cancer" post="(56), and autoimmune disorders (57). For example, the human"/>
 <result pre="studies have shown promising results against hookworm infections (62, 63)," exact="malaria" post="(64, 65), leishmaniasis (66, 67), and schistosomiasis (68, 69)."/>
 <result pre="promising results against hookworm infections (62, 63), malaria (64, 65)," exact="leishmaniasis" post="(66, 67), and schistosomiasis (68, 69). Even though DNA"/>
 <result pre="infections (62, 63), malaria (64, 65), leishmaniasis (66, 67), and" exact="schistosomiasis" post="(68, 69). Even though DNA vaccines offer several advantages"/>
 <result pre="S (Mosquirix) was the first licensed VLP-based vaccine generated against" exact="parasitic disease" post="(114). It is composed of three tandem repeat (R)"/>
 <result pre="(T) epitopes from the circumsporozoite protein of the P. falciparum" exact="malaria" post="parasite, which are displayed on hepatitis B surface particles"/>
 <result pre="of the P. falciparum malaria parasite, which are displayed on" exact="hepatitis" post="B surface particles (HBs-Ag) (S), co-expressed in Saccharomyces cerevisiae"/>
 <result pre="for use in human vaccines and are being studied in" exact="leishmaniasis" post="(121), schistosomiasis (122), tuberculosis (123), and influenza vaccines (124)."/>
 <result pre="in human vaccines and are being studied in leishmaniasis (121)," exact="schistosomiasis" post="(122), tuberculosis (123), and influenza vaccines (124). The combination"/>
 <result pre="vaccines and are being studied in leishmaniasis (121), schistosomiasis (122)," exact="tuberculosis" post="(123), and influenza vaccines (124). The combination of vaccine"/>
 <result pre="being studied in leishmaniasis (121), schistosomiasis (122), tuberculosis (123), and" exact="influenza" post="vaccines (124). The combination of vaccine antigen with different"/>
 <result pre="the vaccine (125, 126). For example, mice immunized with a" exact="yellow fever" post="vaccine containing antigens combined with TLR4 and TLR7 agonists"/>
 <result pre="a TLR4 ligand contained within a PLGA-based nanoparticle plus a" exact="malaria" post="proteins (Pfs25) noted for its poor immunogenicity, improved vaccine"/>
 <result pre="where the mechanism of action is best unpicked. Peripheral blood" exact="eosinophilia" post="is a hallmark feature of the immune response to"/>
 <result pre="production of reactive oxygen species (162), the lung-stage with an" exact="eosinophilia" post="(163, 164), and expulsion from the gut with increased"/>
 <result pre="products have been shown to suppress of Th1/Th17 responses, with" exact="suppression" post="associated with the production of IL-10, IL-22 and transforming"/>
 <result pre="A. caninum ES products were shown to suppress colitis. The" exact="suppression" post="was associated with potent induction of IL-4 and IL-10"/>
 <result pre="for years in the host's small intestine, causing severe iron-deficiency" exact="anemia" post="in humans (1). Pre-clinical hookworm vaccine studies have focused"/>
 <result pre="immunization with Na-ASP-2. It was hypothesized that the induced immediate-type" exact="hypersensitivity" post="was due to the intrinsic structural or biological properties"/>
 <result pre="Pearson et al. also explored a multi-antigen peptide-based vaccine against" exact="schistosomiasis" post="and hookworm containing A291Y peptide from Na-APR-1, a S."/>
 <result pre="health community have focused their vaccine research on hookworm and" exact="ascariasis" post="and somewhat neglected trichuriasis, despite the fact that trichuriasis"/>
 <result pre="and ascariasis and somewhat neglected trichuriasis, despite the fact that" exact="trichuriasis" post="is the second most common STH infection after ascariasis"/>
 <result pre="that trichuriasis is the second most common STH infection after" exact="ascariasis" post="(13). Around 477 million people are estimated to be"/>
 <result pre="(286). Briggs et al. (91) had developed two vaccines against" exact="trichuriasis" post="based on T. muris whey acidic protein (rTm-WAP49) and"/>
 <result pre="severity higher bacterial burden and elevated plasma matrix metalloproteinases in" exact="pulmonary tuberculosis." post="J Infect Dis. (2020) 222:1021–6. 10.1093/infdis/jiaa19432307511 8.SchärFTrostdorfUGiardinaFKhieuVMuthSMartiHet al.. Strongyloides"/>
 <result pre="4:73. 10.3390/tropicalmed402007331035610 21.BeckerSLLiwanagHJSnyderJSAkogunOBelizarioVJrFreemanMCet al.. Toward the 2020 goal of soil-transmitted" exact="helminthiasis" post="control and elimination. PLoS Negl Trop Dis. (2018) 12:e0006606."/>
 <result pre="trial of a DNA vaccine encoding myelin basic protein for" exact="multiple sclerosis." post="Ann Neurol. (2008) 63:611–20. 10.1002/ana.2137018481290 58.AkulovaEMurashevBVerevochkinSMasharskyAAl-ShekhadatRPoddubnyyVet al.. The increase"/>
 <result pre="58:376–83. 10.2478/s11686-013-0151-923990436 64.BejonPMwacharoJKaiOLoweBTodrykSPeshuNet al.Safety, immunogenicity and efficacy studies of candidate" exact="malaria" post="vaccines FP9 and MVA encoding ME-TRAP in Kenyan children"/>
 <result pre="Acta Tropica. (2005) 95:S84. 65.PennyMACamponovoFChitnisNSmithTATannerM. Future use-cases of vaccines in" exact="malaria" post="control and elimination. Parasite Epidemiol Control. (2020) 2020:e00145. 10.1016/j.parepi.2020.e0014532435704"/>
 <result pre="antibody repertoire to target protective sites of pandemic avian H5N1" exact="influenza" post="virus. Sci Transl Med. (2010) 2:15ra5. 10.1126/scitranslmed.300062420371470 97.DietrichJAndreasenLVAndersenPAggerEM. Inducing"/>
 <result pre="Eng. (2018) 19:1–8. 10.1016/j.coche.2017.11.001 114.HawkesN. European medicines agency approves first" exact="malaria" post="vaccine. BMJ. (2015) 351:h4067. 10.1136/bmj.h406726215922 115.PanceA. How elusive can"/>
 <result pre="vaccine. BMJ. (2015) 351:h4067. 10.1136/bmj.h406726215922 115.PanceA. How elusive can a" exact="malaria" post="vaccine be?Nat RevMicrobiol. (2019) 17:129. 10.1038/s41579-018-0148-330626910 116.GuoJZhouASunXShaWAiKPanGet al.. Immunogenicity"/>
 <result pre="multiple antigenic epitopes of Toxoplasma gondii against acute and chronic" exact="toxoplasmosis" post="in mice. Front Immunol. (2019) 10:592. 10.3389/fimmu.2019.0059230984177 117.LeeS-HKimS-SLeeD-HKimA-RQuanF-S. Evaluation"/>
 <result pre="magnitude and quality of immune responses elicited by the ID93" exact="tuberculosis" post="vaccine: first-in-human trial. NPJ Vaccines. (2018) 3:34. 10.1038/s41541-018-0057-530210819 124.KoE-JLeeY-TKimK-HLeeYJungY-JKimM-Cet"/>
 <result pre="to induce isotype-switched IgG antibody responses and protection by T-dependent" exact="influenza" post="vaccine. J Immunol. (2017) 198:279–91. 10.4049/jimmunol.160017327881702 125.McCluskieMKriegA. Enhancement of"/>
 <result pre="influenza vaccine. J Immunol. (2017) 198:279–91. 10.4049/jimmunol.160017327881702 125.McCluskieMKriegA. Enhancement of" exact="infectious disease" post="vaccines through TLR9-dependent recognition of CpG DNA. In: PulendranBAhmedR,"/>
 <result pre="vaccines differentially influence the quality and longevity of responses to" exact="malaria" post="antigen Pfs25. JCI Insight. (2018) 3:120692. 10.1172/jci.insight.12069229769448 130.HotezPJ. The"/>
 <result pre="10.1053/j.gastro.2010.01.04520138044 160.RichardMGrencisRKHumphreysNERenauldJ-CVan SnickJ. Anti-IL-9 vaccination prevents worm expulsion and blood" exact="eosinophilia" post="in Trichuris muris-infected mice. Proc Natl Acad Sci USA."/>
 <result pre="Transl Med. (2020) 12:eaaw3703. 10.1126/scitranslmed.aaw370331894102 175.HaichouXYanWShuhuaXSenLYongWGuangjinSet al.. Epidemiology of human" exact="ancylostomiasis" post="among rural villagers in Nanlin County (Zhongzhou Village), Anhui"/>
 <result pre="cells are associated with therapeutic trichuris trichiura infection in an" exact="ulcerative colitis" post="patient. Sci Transl Med. (2010) 2:60ra88. 10.1126/scitranslmed.300150021123809 183.SmallwoodTBGiacominPRLoukasAMulvennaJPClarkRJMilesJJ. Helminth"/>
 <result pre="are associated with therapeutic trichuris trichiura infection in an ulcerative" exact="colitis" post="patient. Sci Transl Med. (2010) 2:60ra88. 10.1126/scitranslmed.300150021123809 183.SmallwoodTBGiacominPRLoukasAMulvennaJPClarkRJMilesJJ. Helminth"/>
 <result pre="Sci Transl Med. (2010) 2:60ra88. 10.1126/scitranslmed.300150021123809 183.SmallwoodTBGiacominPRLoukasAMulvennaJPClarkRJMilesJJ. Helminth immunomodulation in" exact="autoimmune disease." post="Front Immunol. (2017) 8:453. 10.3389/fimmu.2017.0045328484453 184.RicciNDFiúzaJABuenoLLCançadoGGGazzinelli-GuimarãesPHMartinsVGet al.. Induction of"/>
 <result pre="al.. IL-22 ameliorates intestinal inflammation in a mouse model of" exact="ulcerative colitis." post="J Clin Invest. (2008) 118:534–44. 10.1172/JCI3319418172556 191.YazdanbakhshMvan den BiggelaarAMaizelsRM."/>
 <result pre="Ac-16. Clin Vaccine Immunol. (2007) 14:281–7. 10.1128/CVI.00404-0617267592 210.DiemertDJPintoAGFreireJJariwalaASantiagoHHamiltonRGet al.. Generalized" exact="urticaria" post="induced by the Na-ASP-2 hookworm vaccine: implications for the"/>
 <result pre="secreted extracellular vesicles interact with host cells and prevent inducible" exact="colitis" post="in mice. Front Immunol. (2018) 9:850. 10.3389/fimmu.2018.0085029760697 283.HansenEPKringelHWilliamsARNejsumP. Secretion"/>
</results>
